Industry Advisory Board
The collective wisdom of industry leaders.

Barbara Wirostko, MD, Chair
Board-certified glaucoma specialist, serial entrepreneur, and the CMO and Co-founder of Qlaris Bio, as well as Co-founder and Medical Advisor to MyEyes.
With over 25 years in pharmaceutical drug and device development, she has held executive roles at companies including EyeGate Pharmaceuticals, Jade Therapeutics, Altheos, and Pfizer. Dr. Wirostko is also an Adjunct Professor at the University of Utah, an internationally recognized researcher in exfoliation glaucoma, and an active leader on numerous editorial boards, advisory panels, and nonprofit foundations.

Adrienne Graves, PhD
Visual scientist and global ophthalmology leader with over three decades of experience in clinical development and executive leadership, including as former CEO of Santen Inc.
She has served on numerous corporate and nonprofit boards, including Iveric Bio, Ocular Therapeutix, and the Foundation Fighting Blindness, and currently chairs the RD Fund, the venture arm of FFB. A co-founder of Glaucoma 360 and recipient of multiple industry honors, Dr. Graves is also a Visionary Innovation Mentor at Stanford’s Ophthalmic Innovation Program.

Linda Wirta
Director of Clinical Research at the Eye Research Foundation in Newport Beach, California, which she co-founded in 1998.
With over 25 years of experience, she has led more than 350 Phase I–IV clinical trials in ophthalmology and cosmetic neurotoxins, consistently exceeding enrollment goals. A UCLA graduate and former CRA, Linda oversees a top-tier research team and facility, driving advancements in treatments for glaucoma, dry eye, presbyopia, and other ocular conditions.

Jason Slakter, MD
Internationally recognized retinal disease specialist and biotechnology entrepreneur with over 35 years of clinical and industry experience.
He is a partner at Vitreous Retina Macula Consultants of New York, Clinical Professor at NYU School of Medicine, and founder of the Digital Angiography Reading Center (DARC), now part of Voiant Clinical. Dr. Slakter has advised major pharmaceutical companies on ocular clinical trials, held executive roles at Ohr and Potentia Pharmaceuticals, and serves on multiple scientific advisory boards, with over 100 publications and numerous professional honors.

Eliot Lazar, MD
Distinguished physician with a multifaceted career, widely recognized for his leadership and deep expertise in drug delivery, to regenerative therapy both in ophthalmology and interventional neuroradiology.
He has played a pivotal role in advancing therapeutics from preclinical research to commercialization, collaborating extensively with academia, industry, and the investment sector. With over two decades of experience, Dr. Lazar has built a vast network across the ophthalmology ecosystem, supporting innovation in therapeutics, devices, and diagnostics.